$4.5m raised
$5m won in prizes & grants
Winner of Elon Musk’s XPRIZE 2021
Winner of Shell New Energy Challenge 2023
Winner of L'Oreal GSI 2024
Winner of Horizon Europe 2024
About
Photosynthetic biomanufacturing: The way we will produce everything in the future
More than 200 drug molecules are currently too complex to manufacture using chemistry. We need living cells to make them. Since 1978, Pharma has been using genetically programmable cells like E coli and yeast to manufacture these molecules.
In 2020, scientists discovered a very peculiar kind of microbe, that broke world records.
After two years of extensive fundamental research, we now have the ability to seamlessly reprogramme this special kind of cell and insert unique genetic instructions.
But unlike other cells this cell is unique - it is powered exclusively by the world’s most abundant energy source - sunlight. And feeds exclusively on the world’s most abundant pollutant - CO2.
METRICS
$40 bn
Total market size of products synthesised at cost parity or less
70+
GMO strains engineered
3/7
Biological products in the pipeline successfully synthesised from platform
2
Private contracts delivered
$3.7m
Pre-orders
De-risking critical supply chains
In 2023, over 27% of essential medicines and 54% of pharmaceutical supply were classified by the DLA as “very high risk” due to reliance on unknown supply origins.
CyanoCapture enables users to synthesise $40bn market's worth of high value biomolecules cheaper from anywhere, without Precision Fermentation systems. The platform uses CO2 instead of sugars, requiring less sterility to operate. And can be powered by sunlight or artificial lighting in the absence of chemical energy.
Step 1
The 'Rolls-Royce engine'
A patented genetically engineered cell that boasts the world’s fastest CO2 fixation rate. Robust. Scalable. Doubles every 2 hours.
This is the chassis on which all our applications are built.
Step 2
Reprogramming biology
We turn the chassis into a powerful molecular factory - churning out valuable molecules synthesised entirely from inorganic substances. We feed the cells CO2 continuously with a proprietary mix of inorganic NPK salts. No energy is required other than light to power the process.
Two years of intense development produced patented cloning methods, CRISPR and a proprietary library of genetic parts and unique methods. CyanoCapture has engineered 90+ GMOs.
Step 3
Self-reliant plug-and-play systems
These cells are loaded into Photobioreactor (PBR) systems that integrate seamlessly into point-source emission sites. Inputs are: CO2 (5% v/v), water, NPK salts, and light.
The cells are capable of self-repair and self-replication. Once inoculated, it is a perpetual process of CO2 consumption and synthesis of compounds.
Excess cells and accumulated compounds are continuously harvested.
Step 4
Autonomous on-site biomanufacturing of billion-dollar molecules
$40+ billion worth of high-value compounds can be synthesised using this category-defining manufacturing process.
How it works
Our Core Technology
Pharmaceuticals contribute 4% of global emissions. We enable this industry to decarbonise with zero additional spend by making already-existing high-grossing drug molecules through a category-defining new method of synthesising compounds.
Industrial Enzymes
Pharma compounds
Commodity chemicals
Bioplastics
Bio-graphite
Biocrude oil
Biochar
Growth factors
But why stop at Pharmaceuticals?
Case Study
A $30bn market drug molecule - manufactured entirely from photosynthesis
Though this drug is currently manufactured already by genetically engineered microbes, so far no one has been able to power this process without using chemical energy. We are the first company globally to successfully synthesise this molecule using a 100% photosynthetic process.
By leveraging the CO2-fixing power of our engineered organisms, we can produce this vital compound not only efficiently but at complete cost parity with incumbent manufacturers, even at small scale.
This innovative process enables a carbon-negative pathway for pharmaceutical production. Our groundbreaking technology is currently awaiting FDA approval, poised to revolutionise the availability and carbon footprint of critical medicines globally - especially in austere environments lacking supply chains.
Beyond Pharmaceuticals: carbon capture at industrial scale
Modular • Profitable • Scalable • Low-Energy • Biological Precision •
Products
IFN-Alpha
Peptide drug X
2x more Pharmaceutical products in pipeline (to be announced soon)
20,000L Scale-up project: Non-Pharma grade biomanufacturing (Canada)
kg/month scale production from January 2026. Please enquire about product offtakes.
Q1 2026
Now offering fixed supply agreements with 30%
cheaper than market price guaranteed for first 50 companies.
New website launching soon
